Needham & Company Starts CryoPort (CYRX) at Buy

Needham & Company initiates coverage on CryoPort (NASDAQ: CYRX) with a Buy rating and a price target of $3.50.

Analyst Sean Hannan sees the company as a well-positioned "arms provider" poised to experience material scalable growth in regenerative therapies and the sensitive cryogenic shipping needs to ultimately support therapy transportation to patients.

Hannan sees the company potentially flipping form a "cash burn" to driving positive returns, FCF and EBITDA over the next 12-24 months.

For an analyst ratings summary and ratings history on CryoPort click here. For more ratings news on CryoPort click here.

Shares of CryoPort closed at $2.36 yesterday.

You May Also Be Interested In

• BofA Securities Starts Definium Therapeutics Inc (DFTX) at Buy
• William Blair Downgrades Enovix Corporation (ENVX) to Market Perform
• ThinkEquity Starts Deep Isolation Nuclear (DBHL) at Buy